関連ニュース

Sabra Health Care REIT remains a Buy, supported by improving fundamentals and an attractive valuation amid a strategic pivot to managed senior housing. SBRA reported Q2 2026 normalized AFFO of $0.40 p

Sabra Health Care REIT is rated 'Buy' with a $24.50/share price target, reflecting undervaluation and strong fundamentals. SBRA reported robust Q2 results: 24.7% revenue growth, 13.7% same-store manag

Sabra Health Care REIT remains a Buy, driven by its aggressive pivot into the Seniors Housing Operating Portfolio model. SBRA's SHOP transition offers direct exposure to demographic tailwinds from the